Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 67 от 222

Набира участници Фаза 2

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Triple-Negative Breast Carcinoma

This phase II trial tests how well radiation therapy with pembrolizumab and chemotherapy (paclitaxel or nab-paclitaxel or carboplatin and gemcitabine) works in treating patients with PD-L1 positive triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Carboplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill cancer cells. High dose radiation therapy with pembrolizumab and chemotherapy may effective in treating patients with PD-L1 positive metastatic triple negative breast cancer.

Начало: 22.10.2025 Край: 13.02.2028 Възраст: от 18 г.

United States Emory University NCT06492759

Набира участници Фаза 2

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

Asthma

The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.

Начало: 22.10.2025 Край: 01.06.2028 Възраст: 18–75 г.

Argentina, Brazil, Canada +9 Eli Lilly and Company NCT07219173

Набира участници Фаза 2

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

Ig-E Mediated Food Allergy

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy: This is a Phase 2b randomized, double-blind, placebo-controlled clinical trial evaluating RPT904, a next-generation anti-IgE monoclonal antibody, in people with food allergy. RPT904 is a long-acting antibody that may allow for dosing every 8 to 12 weeks. Approximately 100 participants between the ages of 12 and 55 with documented allergy to at least one of the following foods: peanut, milk, egg, cashew, or walnut will be enrolled. In Part 1 (24 weeks), participants will be randomly assigned to receive RPT904 every 8 or 12 weeks (plus a loading dose at Week 2), or placebo. In Part 2 (24 weeks), participants who received RPT904 will continue on their assigned dosing schedule, and those who previously received placebo will be re-randomized to receive RPT904 either every 8 or 12 weeks (plus a loading dose at Week 26). All participants will attend study visits approximately every 2-6 weeks throughout both Part 1 and Part 2 to maintain blinding, regardless of treatment group or dosing frequency. The study is being conducted at multiple sites. The primary goal is to assess whether RPT904 helps participants tolerate higher amounts of a food allergen without dose-limiting allergic symptoms during a food challenge. The study will also monitor the safety and side effects of RPT904 over time. Each participant is expected to be in the study for about 68 to 74 weeks, including screening, treatment, and follow-up.

Начало: 22.10.2025 Край: 01.01.2028 Възраст: 12–55 г. Лечение

Australia, Canada, United States RAPT Therapeutics, Inc. NCT07220811

Набира участници

SOS for Caregiver Wellbeing

Mental Health Depression and Burden in Caregivers Anxiety Depression Stress +2

Parents and caregivers of children who have a chronic condition carry a large care burden and are at higher risk of having mental health symptoms. This study aims to see if completion of a mental health questionnaire by parents / caregivers at or before the child's paediatric appointment can help identify any symptoms of stress, anxiety or depression. Following the questionnaire, parents / caregivers will be provided with the results of the questionnaire along with an information resource sheet. This will include information on anxiety, stress and depression, as well as different agencies they can contact to get support. Parents / caregivers will be followed up at 3 and 6 months to see if they have any changes to mental health and quality of life, and whether they accessed any support services. The primary aim for this trial is to see whether parents / caregivers find this process acceptable, and whether it can work in a busy hospital clinic.

Начало: 22.10.2025 Край: 28.04.2026 Скрининг

Australia Murdoch Childrens Research Institute NCT07136584

Набира участници Фаза 3

A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

Duchenne Muscular Dystrophy

This is a Phase 3, double-blind, placebo-controlled study with the primary objective of evaluating the efficacy of a single IV infusion of SGT-003 in pediatric ambulant male participants with DMD. The secondary objectives include the evaluation of additional efficacy and safety outcomes. The study will be divided into 2 parts. Participants will be randomized 1:1 to either SGT-003 in Part 1 followed by placebo in Part 2 or to placebo in Part 1 followed by SGT-003 in Part 2. Participants will continue to be monitored in long term follow up (LTFU) for at least 5 years from their SGT-003 dosing date.

Начало: 22.10.2025 Край: 01.01.2034 Възраст: 7–11 г. Лечение

Australia, Canada Solid Biosciences Inc. NCT07160634

Набира участници

A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV System

Severe Aortic Stenosis Valve-in-valve Procedures

Prospective, randomized, controlled, multicenter, international study. Up to 1054 subjects with a severe native calcific aortic stenosis who are determined by the local Heart Team to have an indication for Transcatheter Aortic Valve Replacement (TAVR), will be enrolled in the 'All Comers Randomized Cohort'. Subjects will be randomized 1:1 to receive either the DurAVR® THV System or any commercially available and approved Transcatheter Heart Valve (THV) from the SAPIEN series or the Evolut series and followed for 10 years. After completion of the All Comers Randomized Cohort, up to 446 additional low-risk subjects will be randomized 1:1 in the 'Low Risk Randomized Continued Access Cohort'. Up to 150 subjects with a failed surgical bioprosthesis who are deemed high surgical risk and who need valve-in-valve (ViV) TAVR will be enrolled in a separate nested registry (ViV Registry Cohort) and followed for 5 years. Subjects in the ViV Registry Cohort will only receive the DurAVR® THV.

Начало: 21.10.2025 Край: 01.03.2038 Възраст: от 18 г.

Denmark Anteris Technologies Ltd. NCT07194265

Набира участници Фаза 1

A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis

Rheumatoid Arthritis

The purpose of this study is to determine the safety and tolerability of plamotamab in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.

Начало: 21.10.2025 Край: 01.06.2028 Възраст: от 18 г. Лечение

Georgia, Moldova, New Zealand Xencor, Inc. NCT07230353

Набира участници Фаза 3

CN012-0025: A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease (ADAGIO-3)

Agitation Associated with Alzheimer’s Disease

Trial status: Authorised Reported adverse events (AEs), TEAEs, serious AEs, and TEAEs leading to study withdrawal and deaths, AEs of special interest, Assessment of abnormal involuntary movements or restlessness, Body weight, Blood pressure and heart rate, Laboratory evaluations, Suicidal ideation, Assessment of cognition, Assessment of urinary retention. Incidence of any Treatment-Emergent Adverse Events (TEAEs).

Начало: 21.10.2025 Възраст: от 18 г.

Bulgaria, Croatia, Czech Republic +8 Bristol-Myers Squibb Services Unlimited Company 2024-519994-20-00

Набира участници Фаза 2

A Phase II Open-Label Pilot Trial Assessing the Safety of Anifrolumab in Adult Patients with Primary Antiphospholipid Syndrome (APS). The AnifAPS trial.

Primary Antiphospholipid Syndrome (APS)

Trial status: Authorised Change from baseline (neutralization rate) in type I IFN signature, as assessed by a validated 4-gene panel at weeks 24 and 52, Change from baseline in aCL and aβ2GPI IgG antibody titres and LA status at weeks 12, 24 and 52, Change from baseline in lupus anticoagulant (LA) status at weeks 24 and 52, Change from baseline in complement C3 and C4 levels at weeks 12, 24 and 52, Change from baseline in endogenous thrombin potential, as assessed by a thrombin generation assay at weeks 24 and 52, Change from baseline in the levels of ΝET release markers [i.e., myeloperoxidase (MPO), citrullinated histone H3 (H3Cit) and MPO-deoxyribonucleic acid (DNA) complexes), as assessed by immunofluorescence confocal microscopy and enzyme-linked immunosorbent assay (ELISA) at weeks 24 and 52, Change from baseline in immunothrombosis/thromboinflammation-related gene expression, as assessed by bulk ribonucleic acid (RNA) sequencing at weeks 24 and 52, Change from baseline in the 36-Item Short Form Survey version 2 (SF-36v2) score at weeks 4, 12, 24, 36, 48 and 52, Change from baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) score at weeks 4, 12, 24, 36, 48 and 52, Change from baseline in the Patient Health Questionnaire 9 (PHQ-9) score at weeks 4, 12, 24, 36,.48 and 52, Change from baseline in the Patient’s Global Assessment of health status (PtGA) score at weeks 4, 12, 24, 36, 48 and 52, Change from baseline in the Physician’s Global Assessment of patient’s health status (PhGA) score at weeks 4, 12, 24, 36, 48 and 52, Rate of recurrent venous or arterial thrombotic events within patients with thrombotic APS by week 52, Proportion of patients with livedoid vasculopathy/skin ulcers at baseline achieving CR defined as skin ulcer complete closure as assessed by physical examination, PR defined as ≥50% improvement (wound area reduction) in skin ulcers, and NR defined as no change or worsening of skin ulcers by week 52, Proportion of patients with aPL nephropathy at baseline achieving complete response (CR) defined as proteinuria

Начало: 21.10.2025 Възраст: 18–64 г.

Greece National And Kapodistrian University Of Athens 2025-520918-64-00

Набира участници

Patient Navigation and the Planning Advance Care Together Website to Improve Goals of Care Conversations in Hematopoietic Cell Transplant Survivors, IMPACT-HCT Trial

Hematopoietic and Lymphatic System Neoplasm

This clinical trial evaluates the impact of patient navigation and the Planning Advance Care Together (PACT) website, either alone or in combination with one another, on advanced care planning (ACP) in patients with blood cancers who received a hematopoietic cell transplant (HCT). Engagement in ACP, including having goals of care conversations, improves quality of care at the end of life and supporting this should be included in all cancer survivorship care. Patient navigation is a healthcare service that is designed to guide a patient through the healthcare system and reduce barriers to timely screening follow-up, diagnosis, treatment, and supportive care. PACT is a web-based tool that provides information about ACP, assistance with documents for advanced directives, a supportive network and a forum for discussions about ACP. Patients who engage in ACP are more likely to have higher quality of life at the end of life, receive the care they want, die where they prefer, utilize hospice effectively, and are less likely to receive futile, aggressive care at the end of life. For HCT survivors at ongoing risk of death and other disease-related complications, having a plan in place for care they want is critical. Patient navigation and/or the PACT website may improve ACP, including completion of advance care directives and goals of care conversations, in patients with blood cancers who received an HCT.

Начало: 21.10.2025 Край: 31.07.2026 Възраст: от 18 г.

United States Fred Hutchinson Cancer Center NCT07052630

Набира участници

Subcision With Injection of Poly Deoxyribonucleotide Versus Subcision With Injection of Non-cross Linked Hyaluronic Acid in Rolling Acne Scars Treatment : A Split Face Randomized Controlled Clinical Trial

Rolling Acne Scars

The aim of this study is to evaluate and compare the efficacy and safety of two different injectable agents combined with subcision for treating rolling acne scars. In this split-face clinical trial, each participant will receive subcision on both sides of the face. One side will then be treated with an injection of Polydeoxyribonucleotide (PDRN), while the other side will receive an injection of non-cross linked Hyaluronic acid (HA). The clinical outcomes and improvement in scar appearance will be assessed and compared between both treatments

Начало: 20.10.2025 Край: 20.07.2026 Възраст: от 18 г.

Egypt Cairo University NCT07547956

Набира участници

Children's Health, Respiratory Inflammation and Short-term Air Pollution

Asthma Acute Respiratory

The goal of this study is to see if physical activity in high air pollution is worse than rest in high air pollution.

Начало: 20.10.2025 Край: 01.07.2027 Възраст: 7–11 г.

United Kingdom Queen Mary University of London NCT07431021

Набира участници Фаза 2/3

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia (ITP) ITP - Immune Thrombocytopenia ITP Immune Thrombocytopenic Purpura +3

The main purpose of this study is to confirm the correct dose of efgartigimod IV for treating patients aged 12 to younger than 18 years with chronic immune thrombocytopenia (ITP). The study consists of a double-blinded treatment period (DBTP) in which the participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV. At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first year open-label treatment period (OLTP1). At the end of the first OLTP1, participants may begin a second year (OLTP2). After the OLTP2, the participants will enter a follow-up period (approximately 8 weeks) while off study drug. The participants will be in the study for up to 138 weeks. More information can be found here: https://clinicaltrials.argenx.com/advancejunior

Начало: 20.10.2025 Край: 01.10.2030 Възраст: 12–17 г.

Italy, Poland, Romania +2 argenx NCT07194850

Набира участници

Comparison of Analgesic Efficacy of Suprainguinal Fascia Iliaca and Quadro-iliac Blocks in Hip Fracture Surgery

Post Operative Pain

Hip fractures are common in the elderly and are associated with significant morbidity and mortality. Effective early analgesia is crucial for facilitating mobilization, reducing pulmonary complications, and improving overall outcomes. Although opioids are traditionally used for postoperative pain management, their adverse effects have led to increased interest in multimodal analgesia, particularly peripheral nerve blocks. The suprainguinal fascia iliaca block (SIFI) is a modified technique that allows wider spread of local anesthetic, providing more effective blockade of the femoral, obturator, and lateral femoral cutaneous nerves. The quadro-iliac plane block (QIPB), a recently described interfascial block, is performed at the level of the anterior superior iliac spine and may also affect branches of the lumbar and sacral plexus. While both techniques have been shown to provide effective analgesia and reduce opioid consumption, there is no study directly comparing them. Therefore, this study aims to compare the postoperative analgesic efficacy of SIFI and QIPB in patients undergoing hip fracture surgery.

Начало: 20.10.2025 Край: 15.06.2026 Възраст: от 18 г.

Turkey (Türkiye) Hitit University NCT07546903

Набира участници Фаза 1

A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment

Healthy Hepatic Insufficiency

The purpose of this study is to measure how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function and in healthy participants with normal liver function. The safety and tolerability of LY3537031 will also be evaluated. The study drug will be administered subcutaneously (SC) (under the skin).

Начало: 20.10.2025 Край: 01.08.2026 Възраст: 18–85 г. Фундаментална наука

Hungary, New Zealand, Slovakia Eli Lilly and Company NCT07165002

Набира участници Фаза 1

A Study to Evaluate Single and Multiple Doses of TLC-1180 in Healthy Subjects

Healthy Participants

This phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-1180 after single- and multiple-ascending doses in healthy subjects.

Начало: 20.10.2025 Край: 01.06.2027 Възраст: 18–55 г. Лечение

New Zealand OrsoBio, Inc NCT07300189

Набира участници

PREDICTORS OF FUNCTIONAL STATUS IN CHRONIC NECK PAIN

Neck Pain

Although it has been reported that these problems seen together with neck pain are related to functional limitations and disability, there is still insufficient evidence regarding the relationship between factors affecting functional status and chronic neck pain symptoms in individuals with chronic neck pain. Furthermore, a mixed methodology approach has not been used to comprehensively investigate this relationship. Identifying factors affecting functional status in CNP will help guide the prevention, treatment, and management of neck pain. Therefore, the aim of this study is to investigate the relationships between functional status and psychosocial and bodily functions in CNP.

Начало: 20.10.2025 Край: 20.06.2026 Възраст: 18–65 г.

Turkey (Türkiye) Kutahya Health Sciences University NCT07544108

Набира участници Фаза 3

A Study to Evaluate the Safety and Efficacy of JNT-517 in Participants With Phenylketonuria (PKU)

Phenylketonuria

The goal of this Phase 3, randomized study is to assess the safety, efficacy, tolerability, and pharmacokinetics (PK) of oral JNT-517 in adults (18 years of age or older) with PKU. Participants will receive either JNT-517 or placebo and will be blinded to their treatment assignment. Participants will have a 2 in 3 (or approximately 67%) chance of receiving JNT-517 during the first part of the study which will last approximately six weeks. During the second part of the study every participant who continues in the study will receive one of two doses of JNT-517 for an additional 46 weeks. The study requires a screening period of up to 35 days to ensure dietary stabilization and amino acid levels required to meet study eligibility. In total, participation in the study could last for up to 400 days. Participants will: Take 75 mg JNT-517 or 150 mg JNT-517, or a placebo BID (2x per day) for approximately 365 days; Visit the clinic or have a mobile health nurse visit your home for checkups and tests; Collect urine sample at home and bring to clinic on specified days; Keep a food diary 3 days before each study visit

Начало: 20.10.2025 Край: 01.04.2028 Възраст: от 18 г. Лечение

Australia, Canada, Czechia +7 Otsuka Pharmaceutical Development & Commercialization, NCT06971731

Набира участници Фаза 2

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

Atrial Fibrillation (AF)

This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the study is to see how well REGN7508 and REGN9933 work in patients that get medicine for their atrial fibrillation. The bleeding effects of REGN7508 and REGN9933 will be compared to another medicine (apixaban), which is available on the market to treat and prevent formation of blood clots. The study is looking at several other research questions, including: * What side effects may happen from taking REGN7508 or REGN9933 * How well do the study drugs reduce the risk of having a stroke * How much of REGN7508 or REGN9933 is in the blood at different times * Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the drugs less effective or could lead to side effects)

Начало: 20.10.2025 Край: 21.04.2027 Възраст: от 18 г.

Canada, United States Regeneron Pharmaceuticals NCT07175428

Набира участници

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

Clonal Mast Cell Disease KIT D816V Mutation Suspected KITD816V Mutated Clonal Mast Cell Disease

This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.

Начало: 17.10.2025 Край: 31.10.2028 Възраст: от 18 г.

United States Blueprint Medicines Corporation NCT07143669

1 … 65 66 67 68 69 … 222